• May 26, 2015

    Press Release Spotlight

    Stealth BioTherapeutics Announces Positive Results in Bendavia Heart Failure Study: The PREVIEW Trial

    Read the full article

    Promising findings highlighted at European Society of Cardiology Heart Failure Congress BOSTON – May 26, 2015 – Stealth BioTherapeutics (Stealth), a biopharmaceutical company developing drug candidates for treating mitochondrial dysfunction, today announced positive heart failure results from its PREVIEW study showing Bendavia improved cardiac function for patients. The results were presented at the European Society… Continue Reading >

    Read the full article
  • April 27, 2015

    Press Release Spotlight

    Stealth BioTherapeutics Expands Ocuvia’s Clinical Development into Rare Mitochondrial Optic Neuropathies

    Read the full article

    Ocuvia is one of the first investigational drugs with potential to treat inherited optic neuropathies common in over 20 genetic mitochondrial diseases BOSTON – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing drug candidates for mitochondrial dysfunction, today announced expansion of its ophthalmology program with FDA granting a Type B meeting for inherited optic neuropathies…. Continue Reading >

    Read the full article
  • March 15, 2015

    Press Release Spotlight

    Stealth BioTherapeutics Announces EMBRACE Results: A Phase 2 Clinical Study of Bendavia in Acute Coronary Syndrome

    Read the full article

    Promising heart failure results support strategic focus of Stealth’s cardio-renal program BOSTON, March 15, 2015 — Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing drug candidates for the treatment of diseases involving mitochondrial dysfunction, today announced its EMBRACE results. EMBRACE is a Phase 2 multinational clinical study evaluating Bendavia in patients with acute coronary syndrome… Continue Reading >

    Read the full article
  • February 23, 2015

    Press Release Spotlight

    Stealth BioTherapeutics Presents at NIH Acute Kidney Injury Outcomes Meeting: Bendavia Clinical Results Highlighted During Industry Panel

    Read the full article

    Leading Nephrologists Convene to Advance Novel Therapies, Translational Research and Clinical Trials for AKI BOSTON, Feb. 23, 2015 — Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing drug candidates for the treatment of diseases involving mitochondrial dysfunction, today announced interim Phase 2 clinical results with Bendavia in its cardio-renal program. Bendavia’s results in an acute… Continue Reading >

    Read the full article
  • Press Release Spotlight

    Stealth BioTherapeutics to Participate in Upcoming Investor Conferences

    Read the full article

    Boston, MA – February 23, 2015 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing drug candidates for the treatment of diseases involving mitochondrial dysfunction, today announced that its management team will participate in two upcoming investor conferences. Details of the conferences are as follows: Cowen & Co. 35th Annual Health Care Conference in Boston,… Continue Reading >

    Read the full article
  • February 17, 2015

    Press Release Spotlight

    Stealth BioTherapeutics Initiates a Clinical Study of Bendavia for the Treatment of Orphan Mitochondrial Diseases

    Read the full article

    Trial is one of the first to study Mitochondrial Myopathy, a disorder common to over 270 genetic mitochondrial diseases BOSTON – Feb. 17, 2015 – Stealth BioTherapeutics (Stealth) today announced the initiation of a clinical study of Bendavia in patients with Mitochondrial Myopathy (MM). This study will investigate Bendavia for the treatment of myopathy (muscle… Continue Reading >

    Read the full article
  • February 13, 2015

    Press Release Spotlight

    Stealth BioTherapeutics Announces Promising Data on Ocuvia at 2015 Angiogenesis Conference

    Read the full article

    Ocuvia shows promise in dry age-related macular degeneration (AMD) studies BOSTON, Feb. 11, 2015 — Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing drug candidates for the treatment of diseases involving mitochondrial dysfunction, today announced the findings from several studies of Ocuvia in models of dry age-related macular degeneration (AMD). Ocuvia is an investigational drug… Continue Reading >

    Read the full article

Stealth BioTherapeutics to Present at Jefferies 2015 Healthcare Conference

Presentation will be on Monday, June 1st, 2015 at 10:30 AM ET Boston, MA – May 27, 2015 – Stealth BioTherapeutics (Stealth), a biopharmaceutical company developing drug candidates for treating mitochondrial dysfunction, today announced that Travis Wilson, Chief Executive Officer, will present a corporate overview and development update at the Jefferies 2015 Healthcare Conference in… Continue Reading >

Stealth BioTherapeutics Announces Positive Results in Bendavia Heart Failure Study: The PREVIEW Trial

Promising findings highlighted at European Society of Cardiology Heart Failure Congress BOSTON – May 26, 2015 – Stealth BioTherapeutics (Stealth), a biopharmaceutical company developing drug candidates for treating mitochondrial dysfunction, today announced positive heart failure results from its PREVIEW study showing Bendavia improved cardiac function for patients. The results were presented at the European Society… Continue Reading >

Stealth BioTherapeutics Expands Ocuvia’s Clinical Development into Rare Mitochondrial Optic Neuropathies

Ocuvia is one of the first investigational drugs with potential to treat inherited optic neuropathies common in over 20 genetic mitochondrial diseases BOSTON – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing drug candidates for mitochondrial dysfunction, today announced expansion of its ophthalmology program with FDA granting a Type B meeting for inherited optic neuropathies…. Continue Reading >

Stealth BioTherapeutics Announces EMBRACE Results: A Phase 2 Clinical Study of Bendavia in Acute Coronary Syndrome

Promising heart failure results support strategic focus of Stealth’s cardio-renal program BOSTON, March 15, 2015 — Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing drug candidates for the treatment of diseases involving mitochondrial dysfunction, today announced its EMBRACE results. EMBRACE is a Phase 2 multinational clinical study evaluating Bendavia in patients with acute coronary syndrome… Continue Reading >

Stealth BioTherapeutics Presents at NIH Acute Kidney Injury Outcomes Meeting: Bendavia Clinical Results Highlighted During Industry Panel

Leading Nephrologists Convene to Advance Novel Therapies, Translational Research and Clinical Trials for AKI BOSTON, Feb. 23, 2015 — Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing drug candidates for the treatment of diseases involving mitochondrial dysfunction, today announced interim Phase 2 clinical results with Bendavia in its cardio-renal program. Bendavia’s results in an acute… Continue Reading >